Mice expressing a “hyper-sensitive” form of the CB₁ cannabinoid receptor (CB₁) show modestly enhanced alcohol preference and consumption

David J. Marcus¹,²☯, Angela N. Henderson-Redmond²☯, Maciej Gonek¹, Michael L. Zee¹,², Jill C. Farnsworth¹, Randa A. Amin¹, Mary-Jeanette Andrews¹, Brian J. Davis¹, Ken Mackie¹, Daniel J. Morgan¹,²*¹

¹ Department of Psychological and Brain Sciences and The Linda and Jack Gill Center for Biomolecular Science, Indiana University, Bloomington, IN, United States of America, ² Department of Anesthesiology, Penn State University College of Medicine, Hershey, PA, United States of America

☯ These authors contributed equally to this work.
* djm68@psu.edu

Abstract

We recently characterized S426A/S430A mutant mice expressing a desensitization-resistant form of the CB₁ cannabinoid receptor. These mice display an enhanced response to endocannabinoids and Δ⁹-THC. In this study, S426A/S430A mutants were used as a novel model to test whether ethanol consumption, morphine dependence, and reward for these drugs are potentiated in mice with a “hyper-sensitive” form of CB₁. Using an unlimited-access, two-bottle choice, voluntary drinking paradigm, S426A/S430A mutants exhibit modestly increased intake and preference for low (6%) but not higher concentrations of ethanol. S426A/S430A mutants and wild-type mice show similar taste preference for sucrose and quinine, exhibit normal sensitivity to the hypothermic and ataxic effects of ethanol, and have normal blood ethanol concentrations following administration of ethanol. S426A/S430A mutants develop robust conditioned place preference for ethanol (2 g/kg), morphine (10 mg/kg), and cocaine (10 mg/kg), demonstrating that drug reward is not changed in S426A/S430A mutants. Precipitated morphine withdrawal is also unchanged in opioid-dependent S426A/S430A mutant mice. Although ethanol consumption is modestly changed by enhanced CB₁ signaling, reward, tolerance, and acute sensitivity to ethanol and morphine are normal in this model.

Introduction

Alcohol and morphine use disorders are highly prevalent, affecting an estimated 16.6 million [¹] individuals worldwide and 2.1 million Americans [²], respectively. In 2010, 16,651 deaths in the United States were attributed to overdose from heroin and prescription opioids [³]. Abuse of these drugs inflicts a tremendous financial burden on society, with alcohol dependence alone costing in excess of $223.5 billion annually [⁴,⁵].
The relative lack of long-term efficacy for currently available treatments for alcohol and opiate use disorders illustrates the need for additional therapeutic agents for treating addiction to these drugs [6–10]. Preclinical rodent models have shown that genetic and pharmacological inhibition of the endocannabinoid signaling system (ECS) can profoundly impact ethanol- [11] and opioid- [12,13] motivated behaviors and the physiological responses to these drugs. Treatment with morphine and ethanol cause dopamine release in the nucleus accumbens [14–18]. Mice lacking CB₁ lack ethanol-induced dopamine release in the nucleus accumbens [19,20]. Inhibition of the ECS with rimonabant, a CB₁ inverse agonist, blocks ethanol- but not heroin-stimulated dopamine signaling in the nucleus accumbens [17,21,22]. Conditioned place preference (CPP) for ethanol and morphine are absent in CB₁ knock-out mice [20,23–26]. Dependence on ethanol and opiates is also attenuated in CB₁ deficient mice and rodents treated with rimonabant [24,25,27–29]. Thus, understanding the precise mechanisms through which alcohol influences the ECS and vice versa has the potential to positively impact treatment of alcohol and opioid use disorders.

The ECS consists of three main components: the endogenous ligands (endocannabinoids), the cannabinoid receptors, and the enzymes responsible for the synthesis and catabolism of endocannabinoids. Two main endocannabinoids have been identified, N-arachidonoyl ethanolamine (AEA; anandamide) [30] and 2-arachidonoyl-glycerol (2-AG) [31,32]. CB₁ mediates the psychoactive effects of delta-9-tetrahydrocannabinol (Δ⁹-THC) and is widely expressed throughout the central nervous system [33–38].

Although mice lacking CB₁ clearly show attenuated morphine and ethanol motivated behaviors, it is not well understood whether enhanced activation of the ECS facilitates these behaviors. This study was performed to test the hypothesis that enhanced CB₁ signaling potentiates opiate and alcohol addiction in a preclinical mouse model. These experiments used recently characterized “knock-in” mice expressing a desensitization-resistant form of CB₁ (S426A/S430A) that exhibit markedly enhanced acute responses to endocannabinoids and exogenously administered Δ⁹-THC [39]. First, we examined voluntary ethanol drinking using an unlimited-access, two-bottle choice assay to determine whether S426A/S430A mutant mice consume more ethanol than wild-type controls. Second, conditioned place preference (CPP) assays were performed to measure whether the rewarding properties of morphine, ethanol, or cocaine were potentiated in S426A/S430A mutant mice. Third, we assessed sensitivity to the ataxic and hypothermic effects of ethanol and the recovery of ethanol-induced loss of righting reflex to determine whether a decrease in sensitivity to ethanol was responsible for the increased consumption of ethanol we observed for the S426A/S430A mutants. Fourth, we measured tolerance to the antinociceptive and hypothermic effects of daily morphine injections. Finally, we scored precipitated withdrawal from morphine to determine whether morphine dependence was potentiated in S426A/S430A mutants. The results of this study show that low concentration ethanol consumption is modestly increased in S426A/S430A mutants. However, reward for ethanol, morphine, and cocaine as well as sensitivity and tolerance to ethanol and morphine are unaltered. Thus, our findings suggest that elevated ECS signaling due to disruption of desensitization has only a modest effect on ethanol drinking and that the utility of S426A/S430A mutants for addiction research is limited.

**Materials and methods**

**Subjects**

Experiments were performed using 8–16 week old male age-matched littermate S426A/S430A mutant and wild-type mice. All mice used were either homozygous for the S426A/S430A mutation or homozygous wild-type mice on a C57Bl6/129SvEv hybrid background. Mice used
in this study were backcrossed to the C57BL6 strain for 2–4 generations (F2–F4 backcrosses). Mice used in these experiments were individually (drinking and morphine dependence experiments) or group (all other experiments) housed under a 12:12 h light–dark cycle (lights on 07:00, lights off 19:00) and provided with standard mouse chow ad libitum. All animal care and experimental procedures used in this study were approved by the Institutional Animal Care and Use Committee of the Penn State University College of Medicine or Indiana University Bloomington and conform to the Guidelines of the National Institutes of Health on the Care and Use of Animals.

**Drugs**

A 100% ethanol stock solution was diluted to 20% (v/v) in 0.9% physiological saline. A dose of 1 or 2 g/kg was administered intraperitoneally (IP) in an injection volume of 12.5 ml/kg for experiments on ethanol CPP. To assess ethanol sensitivity, 100% ethanol stock was diluted to either 20 or 30% (v/v) in 0.9% saline and administered IP in doses of 0, 1, 1.5, 2.0, 2.5, 3.0, and 3.5 g/kg. To assess recovery from the sedative effects of ethanol in the loss of righting reflex, 100% ethanol stock was diluted to 25% in 0.9% sterile saline and given by IP injection at a dose of 4 g/kg. For the two-bottle choice drinking assay, ethanol was diluted in tap water to concentrations of 3, 6, 9, 12, 15, and 18% (v/v). Sucrose (Fisher, Pittsburgh, PA) was dissolved into tap water for final concentrations of 1.7 and 4.25% (w/v) while quinine hydrochloride (Avantor, Center Valley, PA) was dissolved to reach final concentrations of 0.03mM and 0.1mM.

Cocaine hydrochloride (NIDA Drug Supply, Bethesda, MD) was dissolved in 0.9% saline and given at a dose of 10 mg/kg IP in an injection volume of 10 ml/kg. Morphine sulfate (NIDA Drug Supply, Bethesda, MD) was dissolved in 0.9% saline and administered subcutaneously (SC) at a dose of 10 mg/kg in an injection volume of 10 ml/kg. A 75mg morphine pellet (NIDA Drug Supply, Bethesda, MD) was implanted subcutaneously to induce morphine dependence. Naloxone hydrochloride (Cayman, Ann Arbor, MI) was dissolved in 0.9% saline and 1 mg/kg was injected IP in a volume of 10 ml/kg to precipitate morphine withdrawal.

**Two-bottle choice drinking**

Ethanol consumption and preference were measured in both male S426A/S430A and wild-type littermates using a modified version of the two-bottle choice assay previously described [40]. Briefly, mice were individually housed and habituated in cages containing two water bottles for six days. Following habituation, one of the water bottles was replaced with a bottle containing 3% ethanol, and mice were given unlimited access to both bottles. Body weights and fluid intakes were recorded and the bottle positions were alternated every other day to control for the development of a side preference. Every eight days, the concentration of ethanol was increased (3%, 6%, 9%, 12%, 15%, and 18% ethanol v/v). Ethanol intake was calculated in grams of ethanol per kilogram (g/kg) of body weight per day and ethanol preference as the volume of ethanol consumed as a percentage of the total fluid consumed. Using this same two-bottle choice paradigm, S426A/S430A mutant and wild-type mice were also assessed for any differences in their taste preference or aversion to 1.7% and 4.25% sucrose (w/v) and 0.03mM and 0.1mM quinine. In all preference and intake studies, four empty cages with water and ethanol bottles were used as controls for spillage and solution evaporation.

**Conditioned place preference (CPP)**

CPP for ethanol (1 and 2 g/kg) was assessed in 31 S426A/S430A mutant and 30 wild-type littermates (14–16 mice/group). Mice were tested in three-chamber place-conditioning boxes (Med Associates, St. Albans, VT) that were housed in sound-attenuating chambers. CPP
experiments for ethanol were done using three-chamber place conditioning boxes and was performed after Dr. Morgan moved from Indiana University to start his own laboratory at the Penn State University College of Medicine. The experiment consisted of four phases: habituation (one session), baseline preference (one session), conditioning (eight sessions) and preference testing (one session). Sessions were scheduled over 11 consecutive days. During the habituation session (Day 1), mice were given 30 minutes to explore all sections of the CPP apparatus to reduce any novelty effects. The following day (Day 2), mice were given 30 minutes of access to the CPP apparatus during which they could explore all chambers to determine their baseline preferences (pre-conditioning scores). Following the baseline preference session, mice were randomly assigned to have ethanol (CS+) or saline (CS-) paired with either the black or white conditioning chambers. During the conditioning phase (Days 3–10), mice were injected with either saline or ethanol (1 or 2 g/kg, IP) on alternating days (i.e., days 3, 5, 7, 9 or 4, 6, 8, 10). Immediately following an injection, mice were confined to the appropriate conditioning chamber for 5 minutes, an optimal amount of time for ethanol place preference conditioning. The order of saline (CS-) and ethanol (CS+) exposure was counterbalanced within groups. After eight total conditioning sessions (4 ethanol and 4 saline), mice were given a 30 minute preference testing session (Day 11) without any drug on board. The amount of time spent in each chamber was recorded and a CPP was determined by assessing the amount of time (in seconds) mice spent in the drug-paired chamber pre- versus post-conditioning.

Separate groups of S426A/S430A mutant and littermate mice were also assessed for CPP to 10 mg/kg of cocaine (IP) and 10 mg/kg of morphine (SC). Although a similar testing paradigm was used [11 days; habituation (1 day), pre-test (1 day), condition (8 days), post-test (1 day)], mice in these experiments were tested at Indiana University in 2 (versus 3) chambered place conditioning boxes (Accuscan Instruments, Columbus, OH) and conditioning sessions lasted for 30 (vs. 5) minutes, an optimal conditioning session length for cocaine place preference. As in the ethanol experiment, the CS+ tactile and visual environment was randomly assigned in an unbiased, counter-balanced subject assignment scheme as previously described [41]. As with ethanol, the development of a CPP was determined by assessing the amount of time (in seconds) that mice spent in the drug (CS+)-paired chamber in pre- versus post-conditioning test sessions.

Ethanol sensitivity

Sensitivity to the hypothermic and ataxic effects of ethanol was examined in 11 wild-type and 19 S426A/S430A mutant mice. Ethanol-induced ataxia was assessed using a rotarod (Med-Associates, St. Albans, VT) set to accelerate from 4 to 40 rpm at a constant rate over 30 seconds. Mice were given six training trials on the rotarod the day prior to ethanol sensitivity training. On testing days, ethanol-induced ataxia was measured in duplicate 30 minutes after injection of ethanol (IP). Rectal temperatures (Physitemp, Clifton, NJ) were taken prior to ethanol administration, and hypothermia was assessed at 30, 60, 120, and 180 minutes post-injection. The effects of 0, 1, 1.5, 2, 2.5, 3, and 3.5 grams per kilogram (g/kg) of ethanol were examined in a single cohort of mice. Mice were allowed at least seven days of recovery between each dose of ethanol, and doses were tested from lowest to highest in order to minimize the effects of tolerance. Sensitivity to the sedative effects of ethanol was also assessed using the loss of righting reflex in 8 wild-type and 7 S426A/S430A mutant mice. Mice were injected with 4 g/kg of ethanol. Following loss of righting reflex (typically in under two minutes), mice were placed upside down in an inverted v-shaped trough so that all four paws were up in the air. Mice were measured for the amount of time (in minutes) it took for them to right themselves. Regaining of the righting reflex was defined as the mouse being able to successfully right itself 3 times within 30 seconds.
Blood ethanol concentration (BECs)

BECs for 9–11 wild-type and 7–8 S426A/S430A mutant mice were assessed at 15, 30, 60 and 120 minutes following a bolus IP injection of 2 g/kg of ethanol. Blood samples (approximately 50 μl) were collected from lateral tail vein nicks using microhematocrit capillary tubes (Fisher Scientific, Pittsburg, PA). Plasma was isolated by centrifugation at 10,000 x g for 10 minutes, and BECs (mg/dL) were assayed using an Analox alcohol analyzer (Analox Instruments, Lunenberg, MA).

Morphine tolerance

S426A/S430A mutant and wild-type littermates were assessed daily for tolerance to the antinociceptive and hypothermic effects of morphine. Mice were injected once daily with 10 mg/kg morphine (SC) for 10 consecutive days. Antinociception was measured using a Columbus Instruments TF-1 tail-flick analgesia meter (Columbus, OH) and a Columbus Instruments Hot Plate Analgesia Meter (Columbus, OH). The heat source was calibrated to elicit a tail-flick latency of 3–4 seconds (intensity setting of 5) in untreated wild-type mice and the hotplate was set at 55˚C. Cutoffs of 10s and 30s for tail-flick and hotplate testing sessions, respectively, were used to avoid tissue damage to the tail and/or paws. Tail-flick and hotplate latencies were measured immediately before morphine treatment and 60 minutes afterwards to calculate the antinociceptive responses as the percentage of maximal possible effect (%MPE) with %MPE = [(post-morphine latency)−(pre-morphine latency)]/[10−(pre-morphine latency)] x 100 for tail-flick and %MPE = [(post-morphine latency)−(pre-morphine latency)]/[30−(pre-morphine latency)] x 100 for the hotplate assay. Hypothermia was assessed by taking body temperatures using a mouse rectal thermometer (Physitemp Instruments, Clifton, NJ), immediately prior to and 60 minutes after morphine injection and was recorded as percent change in body temperature (%ΔBT) = [(pre-morphine temperature)−(post-morphine temperature)]/[pre-morphine temperature] x 100.

Morphine dependence

The severity of morphine dependence was evaluated by scoring various symptoms of naloxone-precipitated morphine withdrawal. Mice were anesthetized using a tabletop laboratory animal anesthesia system (Vetequip Incorporated, Livermore, CA) delivering 4% isoflurane for induction and 2.5% isoflurane for maintenance of anesthesia. Once anesthetized, a two-inch diameter circle was shaved on the neck/back of the mouse. The surgical site was further prepared by cleaning with chlorohexadine, iodine, and then ethanol. Using a scalpel, a 0.25-inch subcutaneous (SC) incision was made perpendicular to the length of the mouse just below the nape of the neck. Using hemostatic forceps, a 75mg morphine pellet (NIDA Drug Supply, Bethesda, MD) was implanted into the pouch created from the incision. The incision was closed with two wound clips, and the mice were then removed from isoflurane and allowed to recover on a heating pad. Seventy-two hours post-implantation, mice received a 1 mg/kg IP injection of naloxone (Cayman, Ann Arbor, MI) to precipitate withdrawal. Immediately after the injection, mice were placed into a transparent plastic enclosure so that a web camera could record precipitated withdrawal for one hour. Jumps, paw tremors, wet dog shakes, and diarrhea were scored from the videos by a single trained and blinded observer.

Data analysis

Two-way mixed factorial analysis of variance (ANOVA) in Prism 6 (Graphpad, La Jolla, CA) was used to analyze ethanol drinking, sucrose and quinine preference, CPP, morphine...
Results

Two-bottle choice drinking

Voluntary ethanol consumption and preference were measured in S426A/S430A mutants and wild-type mice given unlimited 24 hour ethanol access using a two-bottle choice assay. Results from individual repeated measure ANOVAs found a main effect of genotype at 6% ($F_{1,24} = 4.332$, $p = 0.0482$) only. There were no main effects of genotype found at 3% ($p = 0.1477$), 9% ($p = 0.1629$), 12% ($p = 0.3661$), 15% ($p = 0.7294$) or 18% ($p = 0.5623$) ethanol. S426A/S430A mutant mice showed increased consumption (Fig 1A) and preference (Fig 1B) ($F_{1,24} = 5.088$, $p = 0.0335$) for 6% ethanol. The increase in consumption and preference for 6% ethanol was consistent across each of the four (48 hour) measurement sessions (Fig 1A and 1B insets). The lack of any changes in consumption and preference for 15% was also consistent across each.

Fig 1. S426A/S430A mutants prefer and consume more ethanol. A. Consumption (g/kg) of a low (6%) concentration of ethanol was increased for S426A/S430A mutants (red circles and line) relative to wild-type littermates (black lines and squares). Mice were given 24 hour unlimited access to 3%, 6%, 9%, 12%, 15%, and 18% ethanol (v/v) using a two-bottle choice assay. B. S426A/S430A mutants also prefer 6% ethanol more than wild-type littermates. C. Total liquid intake (water plus ethanol) was identical for S426A/S430A mutants and wild-type mice. D. Consumption of 1.75% and 4.25% sucrose was equivalent for S426A/S430A mutants (red bars) and wild-type littermates (black bars). E. S426A/S430A mutants (red bars) and wild-type littermates (black bars) also consume similar amounts of 0.03 mM and 0.1 mM quinine solutions. Averages across the 8 days of intake are shown for each concentration; for both A and B, intakes (collected every 48 hours) are shown in the inset for 6% ethanol. Error bars represent the SEM and data analyses were performed using two-way repeated-measure ANOVA with Bonferroni post-hoc tests (*$p<0.05$). Sample sizes for each group are in parentheses.

https://doi.org/10.1371/journal.pone.0174826.g001
measurement session (S1 and S2 Figs). We found that the total amount of liquid consumed (ethanol and water) was virtually identical for S426A/S430A mutant and wild-type mice (Fig 1C).

Taste preference for sweet- and bitter-flavored solutions was also examined using a two-bottle choice assay to determine whether altered taste preference was responsible for the increased ethanol preference and consumption in the S426A/S430A mutant mice. S426A/S430A mutant and wild-type mice displayed identical taste preference for 1.75% and 4.25% sucrose (Fig 1D). S426A/S430A mutant mice exhibited nearly equivalent taste aversion for 0.03mM and 0.10mM quinine compared to wild-type littermates (Fig 1E).

**Ethanol conditioned place preference**

CPP for 1 and 2 g/kg of ethanol was performed to investigate whether the rewarding effects of ethanol were increased for the S426A/S430A mutant mice. We hypothesized that ethanol CPP would be stronger in S426A/S430A mutants. While there was no effect of conditioning at 1 g/kg of ethanol (Fig 1A) \( F_{1,27} = 1.982; p = 0.1706 \), mice displayed a positive effect of conditioning as evidenced by robust yet equivalent CPP for 2 g/kg of ethanol (Fig 1B) \( F_{1,30} = 17.71; p = 0.0002 \). However, no effect of genotype or a genotype x conditioning interaction was detected.

**Ethanol sensitivity**

The acute hypothermic and ataxic effects of ethanol were measured to test the hypothesis that decreased sensitivity to ethanol might drive the increased ethanol consumption observed in the S426A/S430A mutant mice (Fig 1). This possibility was examined by generating a dose-response curve measuring the ataxic and hypothermic effects of 0 (saline), 1, 1.5, 2, 2.5, 3, and 3.5 g/kg of ethanol in S426A/S430A mutant and wild-type mice. Both S426A/S430A mutant and wild-type mice exhibited a dose-dependent increase in ethanol-induced ataxia (Fig 3A) \( F_{6,168} = 121.5; p < 0.0001 \) that was not different between mutants and wild-type mice.

---

**Endocannabinoid modulation of ethanol and morphine response**

![Figure 2](https://doi.org/10.1371/journal.pone.0174826.g002)
Similar to ataxia, S426A/S430A mutant and wild-type mice also exhibited a dose-dependent increase in ethanol-induced hypothermia (Fig 3B) ($F_{6,168} = 60.82; p<0.0001$) that was not different between mutants and wild-type mice ($p=0.38$). No dose x genotype interaction effects were detected for either ethanol-induced ataxia ($p=0.90$) or hypothermia ($p=0.22$). Recovery of the righting reflex was also measured to assess the magnitude of ethanol-induced sedation in S426A/S430A mutant mice compared to wild-type littermates. Student’s t-test revealed that there was no difference in the amount of time it took for wild-type and S426A/S430A mutant mice to recover their righting reflexes following a challenge dose of 4 g/kg of ethanol (Fig 4) ($t_{13} = 0.890; p = 0.390$).

**Ethanol metabolism**

BECs were measured 15, 30, 60 and 120 minutes following a bolus injection of 2 g/kg (IP) of ethanol in order to determine whether more rapid ethanol metabolism might underlie increased ethanol drinking in S426A/S430A mice. S426A/S430A mutant and wild-type mice exhibited time-dependent metabolism of ethanol (decrease in BEC) (Fig 5) ($F_{3,62} = 89.91; p<0.0001$). While no time x genotype interaction effect was detected ($p = 0.77$), there was a slight overall effect of genotype on ethanol metabolism ($F_{1,62} = 4.825, p = 0.0318$). However, post hoc comparisons failed to yield any genotype differences at any of the time points tested.

**Morphine and cocaine conditioned place preference**

CPP for 10 mg/kg of cocaine and 10 mg/kg morphine were investigated to determine whether the rewarding effects of other drugs of abuse were affected by the S426A/S430A mutation. Cocaine, in particular, was selected as a positive control because it is strongly reinforcing in the CPP paradigm and also because previous work has demonstrated that the ECS is not involved in cocaine CPP [24]. These experiments examining cocaine and morphine CPP were performed using two-chamber CPP boxes (Indiana University) instead of three-chamber CPP boxes (Penn State University). Similar to ethanol, mice collectively displayed a strong CPP for...
10 mg/kg morphine (Fig 6A) ($F_{1,19} = 39.57; p < 0.0001$ with no effect of genotype ($p = 0.53$) or any interaction effect ($p = 0.55$). Mice also displayed a strong CPP for 10 mg/kg cocaine (Fig 6B) ($F_{1,12} = 19.32; p = 0.0009$) with no interaction ($p = 0.96$) or effect of genotype ($p = 0.86$).

Morphine tolerance

Tolerance to the antinociceptive and hypothermic effects of 10 mg/kg morphine was compared between S426A/S430A mutant and wild-type mice (Fig 7). There was a significant effect of time on the development of morphine tolerance using the tail-flick test to assess antinociception (Fig 7A) ($F_{9,477} = 18.98; p < 0.0001$), but there was no effect of genotype ($p = 0.29$) or a genotype x time interaction ($p = 0.95$).

Tolerance to the antinociceptive effects of morphine was also assessed using the hotplate test. Similar to the tail-flick test, there was a significant effect of time on tolerance using the hotplate to assess antinociception (Fig 7B) ($F_{9,198} = 31.28; p < 0.0001$). As with the tail-flick assay, there was no effect of genotype ($p = 0.17$) or a genotype x time interaction ($p = 0.68$).

Tolerance to the hypothermic effect of morphine was also assessed (Fig 7C). Data analysis revealed a significant effect of time ($F_{9,207} = 44.07; p < 0.0001$) but not genotype ($p = 0.12$). Likewise, there was no genotype x time interaction ($p = 0.96$).

Morphine dependence

Symptoms of naloxone-precipitated morphine withdrawal were measured to assess whether morphine dependence was changed in S426A/S430A mutant mice. There was no difference between genotypes in the number of morphine withdrawal-induced jumps ($p = 0.26$), diarrhea ($p = 0.81$), paw tremors ($p = 0.41$), and wet dog shakes ($p = 0.71$). There was a time dependent
**Fig 5. Ethanol metabolism is not altered in S426A/S430A mutants.** Blood ethanol concentrations were measured in S426A/S430A mutants (red bars) and wild-type littermates (black bars) 15, 30, 60 and 120 minutes after a bolus injection (IP) of 2 g/kg of ethanol. Error bars represent the SEM and data analyses were performed using two-way ANOVA with Bonferroni post-hoc tests. Sample sizes for each group are in parentheses.

https://doi.org/10.1371/journal.pone.0174826.g005

**Fig 6. Conditioned place preference for morphine and cocaine is not changed in S426A/S430A mutants.** CPP for either 10 g/kg of morphine (A) or 10 mg/kg cocaine (B) was examined in S426A/S430A mutants and wild-type littermates. Pre-conditioning (black bars) and post-conditioning (red bars) place preference was measured before and after eight days of place preference conditioning. Error bars represent the SEM and data analyses were performed using two-way repeated measure ANOVAs with Bonferroni post-hoc tests (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). Sample sizes for each group are in parentheses.

https://doi.org/10.1371/journal.pone.0174826.g006
decrease in the number of jumps ($F_{1,132} = 56.14; p < 0.0001$), diarrhea episodes ($F_{1,132} = 6.468; p < 0.0001$), and paw tremors over the 60 minute observation period.

**Discussion**

The endocannabinoid system has been shown to be an important regulator of ethanol- [11] and opioid- [12,13] motivated behavior. However, the effect of enhanced endocannabinoid signaling on ethanol and morphine behaviors is less well understood. This study was undertaken to investigate the hypothesis that enhanced CB$_1$ signaling, caused by disruption of CB$_1$ desensitization, potentiates opiate and alcohol addiction. Although ethanol intake and preference were modestly increased in a concentration-dependent manner in the S426A/S430A mutant mouse model, no changes in ethanol reward, sensitivity, or metabolism were detected. There were also no differences in morphine reward or dependence.

A number of experiments were performed to ascertain the possible reason for the modest increase in consumption of 6% ethanol in the S426A/S430A mutant mice. Preference for sucrose solution and aversion for quinine containing solutions were examined to determine whether taste preferences were altered in the mutant mice. However, no differences in taste preference were observed in S426A/S430A mutant mice. The possibility that increased drinking of 6% ethanol in the S426A/S430A mutants was caused by an enhancement of the reinforcing effect of ethanol was assessed by testing ethanol CPP. Robust ethanol CPP (2 g/kg) that was equivalent in magnitude to what was observed in wild-type mice was found for the S426A/S430A mutant mice. Experiments assessing ethanol CPP were done using three chamber boxes as opposed to the two chamber boxes used for ethanol and morphine CPP. Thus a direct comparison of the time spent in the drug-paired (CS') side between these two experiments is not possible due to the presence of the third chamber for the ethanol CPP experiment. This result demonstrates that reward for ethanol is normal and intact in the S426A/S430A mutants and suggests that altered endocannabinoid signaling in the reward circuitry (dopaminergic projections from the ventral tegmental area to the nucleus accumbens) is probably not responsible for increased ethanol consumption in these mutants. Finally, metabolism of a bolus injection of 2 g/kg ethanol was measured to determine whether increased or more rapid ethanol metabolism might underlie the modest increase in ethanol intake and preference observed in the S426A/S430A mutants. There was a significant but slight effect of genotype with wild-type

---

**Fig 7. Tolerance to the antinociceptive and hypothermic effects of morphine is normal in S426A/S430A mutant mice.** Tolerance to the antinociceptive and hypothermic effects of daily treatment with morphine were examined in S426A/S430A mutant mice (red line and circles) and wild-type littermates (black line and squares). Tail-flick antinociception (A), hotplate antinociception (B), and body temperature (C) were measured 60 minutes after SC injection of 10 mg/kg morphine. Data are expressed as mean ± S.E.M and sample sizes for each group are in parentheses. Data analyses were performed using two-way repeated measure ANOVAs with Bonferroni post-hoc tests.

https://doi.org/10.1371/journal.pone.0174826.g007
mice showing slightly elevated BECs overall, there was no difference in BECs between wild-type and S426A/S430A mutants detected at 15, 30, 60 or 120 minutes following ethanol injection, suggesting that ethanol metabolism is not changed for S426A/S430A mutant mice. Thus, our results show an increase in ethanol consumption and preference for dilute ethanol solutions in S426A/S430A mutants that are not due to changes in reward, sensitivity, or metabolism for ethanol.

All of our work was done using only male mice. Given that female mice drink significantly more ethanol than their male counterparts in a 24 hour access free drinking paradigm similar to the one used in our study [42,43] it is possible that we might have seen greater effects of the S426A/S430A mutation on ethanol consumption and CPP had we used female mice instead male mice. For example, when looking at the role of the CB1 receptor in mediating ethanol intake, Hungund and colleagues found that the effect of knocking out the CB1 receptor caused a much more subtle decrease in ethanol intake in male versus female mice [19]. This sex difference was driven entirely by the fact that female wild-type mice drank more than twice the ethanol (10 g/kg/day) than male wild-type mice (5 g/kg/day) resulting in a floor effect. Therefore, it would be interesting to determine whether the S426A/S430A mutation in females results in a greater difference in ethanol intake than we saw in males. Likewise, given that female mice were able to discriminate increasing concentration of ethanol (3 vs 10%) whereas male mice did not [43], it would be interesting to observe whether the S426A/S430A mutation alters the rewarding effects for ethanol CPP at 1 and 2 g/kg of ethanol in female mice.

Morphine-induced CPP and intravenous self-administration are completely absent in mice lacking CB1 receptors [24–26]. However, CPP for cocaine is not altered in CB1 knock-out (KO) mice [24]. Pharmacological blockade of CB1 using SR141617A (Rimonabant) attenuated CPP for morphine [44,45]. Direct activation of cannabinoid receptors using WIN 55,212–2 or URB597, an inhibitor of fatty acid amide hydrolase (FAAH), does not impact morphine CPP [46]. However, less is known about the effects of CB1 activation on morphine CPP. Therefore, S426A/S430A mutant mice were used to test whether enhanced endocannabinoid signaling, caused by blocking CB1 desensitization, might potentiate morphine CPP. Consistent with previous work using URB597 to potentiate endocannabinoid signaling [46], there was no evidence of increased morphine CPP in S426A/S430A mutant mice.

Previous work demonstrates evidence of bi-directional cross-tolerance between opioid and cannabinoid agonists [47,48]. Recent work demonstrated tolerance for WIN 55,212–2, CP55,940, and Δ⁹-THC in morphine-tolerant rhesus monkeys [49]. Tolerance to Δ⁹-THC was delayed in mice lacking pre-proenkephalin, the precursor for the opioid peptide enkephalin [50]. Chronic treatment of rodents with either Δ⁹-THC or CP55,940 causes cross-tolerance to morphine analgesia [48,51]. While co-administration of AM251, a CB1 inverse agonist, inhibited tolerance to the antinociceptive effects of chronic morphine [52]. Activation of CB1 with Δ⁹-THC [53] or CP55,940 [54] attenuated tolerance to the antinociceptive effects of morphine. Additional work found that chronic morphine treatment produced a large reduction of 2-AG levels in the brain, raising the possibility that decreased 2-AG might be involved in the development of morphine tolerance [51].

Therefore, tolerance to morphine was examined in S426A/S430A mutants based on strong evidence of interplay between the opioid and endocannabinoid systems and bi-directional cross-tolerance for agonists of these receptors. Tolerance for the antinociceptive effects of morphine in either the tail-flick or hotplate assay did not differ between S426A/S430A mutants and wild-type mice. This finding contrasts slightly with previous studies demonstrating that cannabinoid receptor activation can attenuate or prevent tolerance for morphine [53,54]. However, previous studies looked at how co-administration of CB1 agonists with morphine could reduce morphine tolerance [53,54], whereas the current study only looked at how
morphine tolerance differed as a function of our desensitization-resistant S426A/S430A mutation. In addition, it is worth noting that constitutive activation of our S426A/S430A knock in mutation might result in subtle neuroadaptive changes within the endocannabinoid system that could mask subtle effects on morphine tolerance.

Treatment of rats or mice with rimonabant has been shown to reduce opioid dependence, suggesting a key role for CB₁-mediated signaling in this phenomenon [28,55]. In addition, mice lacking CB₁ receptors exhibit reduced morphine dependence [25,27,29]. However, increasing endocannabinoid levels using inhibitors of endocannabinoid catabolic enzymes also attenuates symptoms of precipitated withdrawal in morphine-tolerant mice [56,57]. Therefore, we wanted to test whether physical signs of morphine dependence were altered in S426A/S430A mutants. S426A/S430A mutants displayed no change in the number of morphine withdrawal-induced jumps, diarrhea episodes, paw tremors, or wet dog shakes compared to wild-type controls. This suggests that the modest enhancements in endocannabinoid signaling observed in the S426A/S430A mutants are not sufficient to alter morphine withdrawal.

Although a previous examination did not find altered endocannabinoid levels or CB₁ protein in the brains of S426A/S430A mice under baseline conditions, we did not exhaustively examine these ECS components in all parts of the brain associated with drug taking behaviors and dependence [39]. Nor did we examine endocannabinoid or CB₁ levels in mice given either morphine or ethanol or mice allowed to voluntarily drink ethanol. Thus, it is possible that homeostatic regulation of endocannabinoid signaling might restore normal balance and endocannabinoid tone in parts of the brain responsible for ethanol- and morphine-motivated behaviors. For example, it is possible that CB₁ and endocannabinoid levels might be down-regulated in regions of the brain associated with morphine physical dependence such as the amygdala and noradrenergic neurons in the hindbrain. In a separate study, we did not observe evidence of metabolic abnormalities in S426A/S430A mutant compared to wild-type controls fed a routine or high fat diet [58]. One possible explanation for the lack of phenotype observed in these mutants could be that the S426A/S430A mutation is not sufficient to confer significantly enhanced responses to relatively low basal levels of endocannabinoids in tissues or circulation. Therefore, we conclude that this model might have limited utility for studying the effects of enhanced ECS signaling.

This work is timely given the prevalence and legalization (in some states) of recreational cannabis consumption, which represents a major source of excess ECS activation in humans. Additionally, expression of endocannabinoids in circulation and in tissue are increased for a number of disease states including obesity, cancer, and neurodegeneration. Thus, understanding the potential impact of elevated ECS signaling on developing dependence to drugs of abuse such as morphine and ethanol has tremendous relevance for human health. Although we observe increased ethanol drinking in the S426A/S430A mutants our results suggest that modest increases in endocannabinoid signaling, such as those that occur in these mutants, do not broadly impact drug reward and dependence.

Supporting information

S1 Fig. Daily consumption of 15% ethanol. (TIF)
S2 Fig. Daily preference for 15% ethanol. (TIF)
Acknowledgments

The authors wish to thank James Wager-Miller for technical assistance.

This work has been supported by NIH grants DA036385 (DJM), DA037355 (DJM), DA011322 (KM), DA021696 (KM) and is funded, in part, by grant 4100057673 from the Pennsylvania Department of Health using Tobacco CURE Funds (DJM). Additional support was provided by the Indiana University METACyt Initiative (funded in part by a grant from the Lilly Foundation) and the Linda and Jack Gill Center for Biomolecular Science.

Author Contributions

Conceptualization: D. Marcus AHR D. Morgan KM.

Formal analysis: D. Marcus AHR D. Morgan.

Funding acquisition: D. Morgan KM.

Investigation: D. Marcus AHR MG MLZ RA MJA D. Morgan BD JF.

Methodology: D. Morgan KM.

Project administration: D. Morgan.

Resources: KM.

Supervision: D. Morgan.

Validation: D. Marcus AHR D. Morgan.

Visualization: D. Marcus AHR D. Morgan.

Writing – original draft: D. Marcus AHR D. Morgan KM.

Writing – review & editing: D. Marcus AHR MLZ D. Morgan KM.

References

1. World Health Organization. Management of Substance Abuse Team. (2011) Global status report on alcohol and health. Geneva, Switzerland: World Health Organization. xii, 286 p.

2. Administration. SAaMHS (2013) Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. National Survey on Drug Use and Health series. Rockville, MD: Dept. of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. pp. v.

3. Mack KA (2013) Drug-induced deaths—United States, 1999–2010. MMWR Surveill Summ 62 Suppl 3: 161–163.

4. Bouchery EE, Harwood HJ, Sacks JJ, Simon CJ, Brewer RD (2011) Economic costs of excessive alcohol consumption in the U.S., 2006. Am J Prev Med 41: 516–524. https://doi.org/10.1016/j.amepre.2011.06.045 PMID: 22011424

5. Grant BF, Dawson DA, Stinson FS, Chou SP, Dufour MC, Pickering RP (2004) The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991–1992 and 2001–2002. Drug Alcohol Depend 74: 223–234. https://doi.org/10.1016/j.drugalcdep.2004.02.004 PMID: 15194220

6. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE (2000) A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 343: 1290–1297. https://doi.org/10.1056/NEJM200011023431802 PMID: 11058673

7. Latt NC, Jurd S, Houseman J, Wutzke SE (2002) Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust 176: 530–534. PMID: 12064984

8. Kranzler HR, Wesson DF, Billiot L (2004) Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res 28: 1051–1059. PMID: 15252291
9. Foa EB, Yusko DA, McLean CP, Suvak MK, Bux DA Jr, Oslin D, et al. (2013) Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial. JAMA 310: 488–495. https://doi.org/10.1001/jama.2013.8268 PMID: 23925619
10. Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295: 2003–2017. https://doi.org/10.1001/jama.295.17.2003 PMID: 16670409
11. Henderson-Redmond AN, Guindon J, Morgan DJ (2015) Roles for the endocannabinoid system in ethanol-motivated behavior. Prog Neuropsychopharmacol Biol Psychiatry.
12. Befort K (2015) Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies. Front Pharmacol 6: 6. https://doi.org/10.3389/fphar.2015.00006 PMID: 25698968
13. Scavone JL, Sterling RC, Van Bockstaele EJ (2013) Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience 248: 637–654. https://doi.org/10.1016/j.neuroscience.2013.04.034 PMID: 23624062
14. Tanda G, Pontieri FE, Di Chiara G (1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276: 2048–2050. PMID: 9197269
15. Chen JP, Paredes W, Li J, Smith D, Lowinson J, Gardner EL (1990) Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology (Berl) 102: 156–162.
16. Cheer JF, Wassum KM, Heien ML, Phillips PE, Wightman RM (2004) Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci 24: 4393–4400. https://doi.org/10.1523/JNEUROSCI.0529-04.2004 PMID: 15128853
17. Cheer JF, Wassum KM, Sombers LA, Heien ML, Ariasen JL, Aragona BJ, et al. (2007) Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. J Neurosci 27: 791–795. https://doi.org/10.1523/JNEUROSCI.4152-06.2007 PMID: 17251418
18. Weiss F, Lorang MT, Bloom FE, Koob GF (1993) Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. J Pharmacol Exp Ther 267: 250–258. PMID: 8229752
19. Hungund BL, Szakall I, Adam A, Basavrajappa BS, Vadasz C (2003) Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J Neurochem 84: 698–704. PMID: 12652514
20. Thanos PK, Dimitrakakis ES, Rice O, Gifford A, Volkow ND (2005) Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors. Behav Brain Res 164: 206–213. https://doi.org/10.1016/j.bbr.2005.06.021 PMID: 16140402
21. Caille S, Parsons LH (2003) SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats. Eur J Neurosci 18: 3145–3149. PMID: 14656311
22. Caille S, Parsons LH (2006) Cannabinoid modulation of opiate reinforcement through the ventral striato-pallidal pathway. Neuropsychopharmacology 31: 804–813. https://doi.org/10.1038/sj.npp.1300848 PMID: 16123766
23. Houchi H, Babovic D, Piereffe O, Ledent C, Daoust M, Naassila M (2005) CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors. Neuropsychopharmacology 30: 339–349. https://doi.org/10.1038/sj.npp.1300568 PMID: 15383833
24. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2000) Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci 12: 4038–4046. PMID: 11096600
25. Ledent C, Valverde O, Cossu G, Petitje F, Aubert JF, Beslot F, et al. (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283: 401–404. PMID: 9888857
26. Cossu G, Ledent C, Fattore L, Imperato A, Bohme GA, Parmentier M, et al. (2001) Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res 118: 61–65. PMID: 11163534
27. Racz I, Bilkei-Gorzo A, Toth ZE, Michel K, Palkovits M, Zimmer A (2003) A critical role for the cannabinoid CB1 receptors in alcohol dependence and stress-stimulated ethanol drinking. J Neurosci 23: 2453–2458. PMID: 12657705
28. Mas-Nieto M, Pommier B, Tzavara ET, Caneparo A, Da Nascimento S, Le Fur G, et al. (2001) Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol 132: 1809–1816. https://doi.org/10.1038/sj.bjp.0703990 PMID: 11309253

29. Lichtman AH, Shelik SM, Loh HH, Martin BR (2001) Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther 298: 1007–1014. PMID: 11504797

30. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946–1949. PMID: 1470919

31. Stella N, Schweitzer P, Piomelli D (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388: 773–778. https://doi.org/10.1038/42015 PMID: 9285589

32. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al. (1995) 2-Arachidonoylethanolamide: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215: 89–97. PMID: 7575630

33. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34: 605–613. PMID: 2848184

34. Mailleux P, Vanderhaeghen JJ (1992) Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48: 655–668. PMID: 1376455

35. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11: 563–583. PMID: 1992016

36. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87: 1932–1936. PMID: 2308954

37. Matsuda LA, Lollait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Identification of a cannabinoid receptor in rat brain: a novel ligand for the cannabinoid receptor. Nature 346: 561–564. https://doi.org/10.1038/346561a0 PMID: 2165569

38. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83: 393–411. PMID: 9460749

39. Morgan DJ, Davis BJ, Kearns CS, Marcus D, Cook AJ, Wager-Miller J, et al. (2014) Mutation of putative GRK phosphorylation sites in the cannabinoid receptor 1 (CB1R) confers resistance to cannabinoid tolerance and hypersensitivity to cannabinoids in mice. J Neurosci 34: 5152–5163. https://doi.org/10.1523/JNEUROSCI.3445-12.2014 PMID: 24719095

40. Thiele TE, Marsh DJ, Ste Marie L, Bernstein IL, Palmiter RD (1998) Ethanol consumption and resistance are inversely related to neuropeptide Y levels. Nature 396: 366–369. https://doi.org/10.1038/24614 PMID: 9845072

41. Cunningham CL, Gremel CM, Groblewski PA (2006) Drug-induced conditioned place preference and aversion in mice. Nat Protoc 1: 1662–1670. https://doi.org/10.1038/nprot.2006.279 PMID: 17487149

42. Melo JA, Shendure J, Pociask K, Silver LM (1996) Identification of sex-specific quantitative trait loci controlling alcohol preference in C57BL/6 mice. Nat Genet 13: 147–153. https://doi.org/10.1038/ng0696-147 PMID: 8640219

43. Middaugh LD, Kelley BM, Bandy AL, McGroarty KK (1999) Ethanol consumption by C57BL/6 mice: influence of gender and procedural variables. Alcohol 17: 175–183. PMID: 10231165

44. Singh ME, Vertu AN, McGregor IS, Mallet PE (2004) A cannabinoid receptor antagonist attenuates conditioned place preference but not behavioural sensitization to morphine. Brain Res 1026: 244–253. https://doi.org/10.1016/j.brainres.2004.08.027 PMID: 15488486

45. Chaparon F, Soubrie P, Puech AJ, Thiebot MH (1998) Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology (Berl) 135: 324–332.

46. De Carvalho CR, Pamplona FA, Cruz JS, Takahashi RN (2014) Endocannabinoids underlie reconsolidation of hedonic memories in Wistar rats. Psychopharmacology (Berl) 231: 1417–1425.

47. Hine B (1985) Morphine and delta 9-tetrahydrocannabinol: two-way cross tolerance for antinociceptive and heart-rate responses in the rat. Psychopharmacology (Berl) 87: 34–38.

48. Thorat SN, Bhargava HN (1994) Evidence for a bidirectional cross-tolerance between morphine and delta 9-tetrahydrocannabinol in mice. Eur J Pharmacol 260: 5–13. PMID: 7957626

49. Gerak LR, Zanettini C, Koek W, France CP (2015) Cross-tolerance to cannabinoids in morphine-tolerant rhesus monkeys. Psychopharmacology (Berl).

---

Endocannabinoid modulation of ethanol and morphine response

---

PLOS ONE | https://doi.org/10.1371/journal.pone.0174826 April 20, 2017 16 / 17
50. Valverde O, Maldonado R, Valjent E, Zimmer AM, Zimmer A (2000) Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. J Neurosci 20: 9284–9289. PMID: 11125007

51. Vigano D, Rubino T, Vaccani A, Bianchessi S, Marmorato P, Castiglioni C, et al. (2005) Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. Psychopharmacology (Berl) 182: 527–536.

52. Trang T, Sutak M, Jhamandas K (2007) Involvement of cannabinoid (CB1)-receptors in the development and maintenance of opioid tolerance. Neuroscience 146: 1275–1288. https://doi.org/10.1016/j.neuroscience.2007.02.031 PMID: 17395382

53. Cichewicz DL, Welch SP (2003) Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 305: 812–817. https://doi.org/10.1124/jpet.102.046870 PMID: 12606610

54. Fischer BD, Ward SJ, Henry FE, Dykstra LA (2010) Attenuation of morphine antinociceptive tolerance by a CB(1) receptor agonist and an NMDA receptor antagonist: Interactive effects. Neuropsychopharmacology 58: 544–550. https://doi.org/10.1016/j.neuropharmacology.2009.08.005 PMID: 19699755

55. Rubino T, Massi P, Vigano D, Fuzio D, Parolaro D (2000) Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome. Life Sci 66: 2213–2219. PMID: 10834304

56. Ramesh D, Gamage TF, Vanuytsel T, Owens RA, Abdullah RA, Niphakis MJ, et al. (2013) Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antithrombotic effects in morphine-dependent mice. Neuropsychopharmacology 38: 1039–1049. https://doi.org/10.1038/npp.2012.269 PMID: 23303065

57. Ramesh D, Ross GR, Schlosburg JE, Owens RA, Abdullah RA, Kinsey SG, et al. (2011) Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice. J Pharmacol Exp Ther 339: 173–185. https://doi.org/10.1124/jpet.111.181370 PMID: 21719468

58. Marcus DJ, Zee ML, Davis BJ, Haskins CP, Andrews MJ, Amin R, et al. (2016) Mice Expressing a "Hyper-Sensitive" Form of the Cannabinoid Receptor 1 (CB1) Are Neither Obese Nor Diabetic. PLoS One 11: e0160462. https://doi.org/10.1371/journal.pone.0160462 PMID: 27501235